Compare Manulife Financial Corporation (MFC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Neurocrine Biosciences Inc — how do they compare? Manulife Financial Corporation trades at $42.5 (market cap $69.48B), while Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B). The key difference: Manulife Financial Corporation is far larger — about 4.8× Neurocrine Biosciences Inc's market cap, and Manulife Financial Corporation pays a 3.23% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manulife Financial Corporation for 119 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MFC | NBIX | |
|---|---|---|
Market Cap | $69.48B | $14.36B |
Volume | 1,347,508 | 1,237,180 |
Sector | Financials | Health |
52-Week High | $44.77 | $185.50 |
52-Week Low | $31.64 | $123.10 |
Typical Hold Time | 119 Days | 23 Days |
Enterprise Value | $64.75B | $14.37B |
Dividend Yield | 3.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MFC trades at $42.33, up 1.58% today, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth from $53.01B in 2025 to projected $57.5B in 2026, with net income margins around 11%. Recent institutional investments from Bank of America and executive appointments signal confidence. However, the stock trades above the $34.24 consensus price target, suggesting limited near-term upside.
The outlook remains mixed with solid fundamentals but valuation concerns. Investment opportunity lies in continued Asia growth and insurance sales momentum, while risks include premium valuation and potential earnings volatility. Analyst consensus leans bullish with 57% buy ratings, but technical indicators warn of near-term pressure.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
